Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Dublin, May 12, 2026 (GLOBE NEWSWIRE) -- The "Saudi Arabia Cement Industry Market Size & Forecast by Value and Volume Across 100+ Market Segments by Cement Products, Distribution Channel, Market...
-
Dublin, May 12, 2026 (GLOBE NEWSWIRE) -- The "Europe Cement Industry Market Size & Forecast by Value and Volume Across 100+ Market Segments by Cement Products, Distribution Channel, Market...
-
BRISBANE, Australia, May 12, 2026 (GLOBE NEWSWIRE) -- North American lithium producer Elevra Lithium Limited (“Elevra or Company”) (ASX:ELV; NASDAQ:ELVR) announced today the outcomes of an Updated...
-
New York City, NY, May 09, 2026 (GLOBE NEWSWIRE) -- If you have spent months on calorie-restricted diets, hours on treadmills, or considered expensive prescription weight loss medications only to...
-
ROLLING MEADOWS, Ill., May 08, 2026 (GLOBE NEWSWIRE) -- RYTHM, Inc. (Nasdaq: RYM) today announced that Navy Pier has named RYTHM, Chicago’s flagship THC brand, as its official THC beverage partner,...
-
LAKEWOOD RANCH, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced its newest community, Monterey at Lakewood Ranch...
-
PRESS RELEASE NON-REGULATED INFORMATIONLuxembourg, May 7, 2026, 5:55 PM ...
-
For its 44th year, the NAHB International Builders' Show® once again features The New American Home® with Las Vegas–based Blue Heron as its builder, returning for the fourth time. LAS VEGAS, May 06,...
-
IRVINE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Habit, the California-based restaurant company renowned for its award-winning Charburgers grilled over an open flame, signature sandwiches, fresh...
-
Phase 3 wet AMD trials, LUGANO and LUCIA, remain on track with topline data expected beginning mid-2026 –Phase 3 DME clinical trials, COMO and CAPRI, rapidly advancing with over one-third of patients...